India’s food regulator has opened three separate adjudication cases against Nestlé India over infant nutrition products, putting label claims, e-commerce listings and nutritional composition under the same compliance spotlight.
What FSSAI is examining
The Food Safety and Standards Authority of India has initiated cases involving NAN Excella Pro Stage 1 and Lactogen Pro 1, and a third case connected to a follow-up formula. For the first two products, the regulator flagged claims around “5 HMOs,” whey protein, and the description of whey protein as easy to digest. The third case relates to a follow-up formula sample that was found to be sub-standard for biotin content in laboratory analysis, including on re-analysis.
“Our products are fully compliant with all the applicable regulations,” a Nestlé India spokesperson said, adding that the product labels were approved by the FSSAI expert committee.
FSSAI said it sought clarifications from Nestlé India before proceeding with the cases. The regulator found the two products to be in contravention of Regulation 4(2) of the Food Safety and Standards (Foods for Infant Nutrition) Regulations, 2020. It also cited the Infant Milk Substitutes, Feeding Bottles and Infant Foods (Regulation of Production, Supply and Distribution) Act, 1992, which prohibits advertising and promotion of covered products.
Why it matters for brand teams
This is not only a product-quality story. It is a marketing compliance story because FSSAI’s examination included how Nestlé India’s infant nutrition products and promotional material appeared on e-commerce platforms.
For infant nutrition, India’s regulatory framework goes beyond product composition. Claims and promotional material intended to increase saleability are restricted. That means marketplace product pages, claim badges, and digital descriptions can create the same exposure as a traditional advertisement.
- Infant food claims that sound nutritional can still be treated as promotional.
- E-commerce listings are now part of regulatory scrutiny, not just media ads.
- Label approval by an expert committee may not be enough if a later regulator review disagrees.
- Nutritional composition issues can trigger separate adjudication even when labels are not the concern.
The market and communication signal
Nestlé India shares fell as much as 2.8% during the September 18 trading session, according to market reports, showing how quickly a regulatory action can become an investor-facing issue. The company says it has submitted a detailed response and will continue to work with FSSAI.
A practical checklist for marketers
Brand teams working on infant nutrition or other highly regulated categories should treat every product page claim as a compliance asset. Before launching or updating a listing, verify the claim language against the specific regulation, review any expert-committee approval trail, and check whether the product’s tested nutritional values match the label and promotional copy.
The FSSAI cases are a reminder that digital shelf content is not separate from product regulation. For marketing leaders, the task is to connect legal, regulatory, and e-commerce teams early enough to catch a claim before it becomes a notice.
Source: Storyboard18
